The FDA approved PD-L1 (IHC) 22C3 pharmDx companion diagnostic test for KEYTRUDA® (pembrolizumab) is now available at CGI to assess PD-L1 expression in Non-Small Cell Lung Cancer
Trending Articles
More Pages to Explore .....
The FDA approved PD-L1 (IHC) 22C3 pharmDx companion diagnostic test for KEYTRUDA® (pembrolizumab) is now available at CGI to assess PD-L1 expression in Non-Small Cell Lung Cancer